Nitrofurantoin: uses, dosing, side effects & brands

Nitrofurantoin is a nitrofuran antibacterial used to treat Escherichia Coli Infections, Klebsiella Infections, Staphylococcal Infections, Urinary Tract Infections.

The FDA classifies nitrofurantoin as a nitrofuran antibacterial. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The label contraindicates nitrofurantoin in pregnant women at term (38 to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent, because of the risk of hemolytic anemia in the newborn (immature erythrocyte enzyme systems). For earlier pregnancy, the label says published epidemiological studies have reported inconsistent findings on first-trimester use and major birth defects and cannot definitively establish the presence or absence of risk; the limited studies available have not identified drug-associated risks of major birth defects, miscarriage, or other adverse outcomes, and animal studies showed no fetal harm at up to 6 times the human dose. Anyone who is or may become pregnant should discuss use with their prescriber. This is what nitrofurantoin's FDA label says; whether to use it in pregnancy is your prescriber's decision.

The elimination half-life of nitrofurantoin is about 20 minutes (roughly 0.3 hours) for the parent drug in adults with normal kidney function — that is how long the body takes to clear half of a dose. The FDA/DailyMed nitrofurantoin labels (Macrobid, Macrodantin, Furadantin) do not print an explicit numeric elimination half-life; the Macrodantin label states the drug is "readily absorbed and rapidly excreted in urine," with about 35-38% of a 100 mg dose recovered unchanged in urine over 24 hours and low blood levels at therapeutic doses. Published pharmacology puts the serum (plasma) half-life at about 20 minutes, so the parent drug clears from the blood within a few hours. Nitrofurantoin is not a prodrug and has no active metabolite that outlasts it. Because it is eliminated mainly by the kidneys, blood levels run higher and it clears more slowly when kidney function is reduced — it is contraindicated when creatinine clearance is under 60 mL/min, and older adults (who more often have reduced kidney function) need extra caution. It is dosed several times a day precisely because it leaves the bloodstream so quickly; this short blood half-life is not a drug-test detection window. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run nitrofurantoin against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 4 nitrofurantoin-containing products in the U.S.: Nitrofurantoin, Furadantin, Furalan and Ivadantin. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, nitrofurantoin is currently marketed as capsule, suspension, tablet and injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 2 generic nitrofurantoin products alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

The FDA's Enforcement database lists 2 recall records whose product description mentions nitrofurantoin. The most recent: Nitrofurantoin Capsules (Dec 4, 2024). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

The usual complaints with oral nitrofurantoin (Macrobid, Macrodantin, Furadantin) are nausea, loss of appetite, headache, and dizziness — and they usually fade once the course ends, which for a bladder infection is typically only 5 to 7 days. Nitrofurantoin also turns urine dark yellow or brown. That is harmless staining from the drug itself, not blood, and it stops when you stop the medicine. The single most useful thing you can do is take every dose with food or milk: the FDA label instructs this because food both improves how much drug you absorb — bioavailability rises by about 40% — and cuts the nausea.

Get emergency care for sudden fever, chills, cough, chest pain, or shortness of breath. Nitrofurantoin's defining serious risk is a lung reaction: the FDA label leads its warnings with acute, subacute, or chronic pulmonary reactions, instructs that the drug be discontinued if they occur, and states that reports have cited pulmonary reactions as a contributing cause of death. The acute form usually appears within the first week of treatment and reverses when the drug is stopped. Also call your prescriber the same day for: yellowing of the eyes or skin, dark urine with right-upper-belly pain or severe fatigue (the label lists hepatitis, cholestatic jaundice, chronic active hepatitis and hepatic necrosis as rare, with fatalities reported); new numbness, tingling, burning, or weakness in the hands or feet (peripheral neuropathy, which the label says may become severe or irreversible, also with fatalities reported); unusual paleness, breathlessness on mild exertion, or very dark urine (hemolytic anemia, especially with G6PD deficiency); severe or bloody diarrhea during or after treatment (C. difficile).

The FDA label lists these as contraindications: creatinine clearance under 60 mL/min or a clinically significant elevated serum creatinine (also anuria or oliguria), a previous history of cholestatic jaundice or liver dysfunction from nitrofurantoin, known hypersensitivity, pregnancy at term (38 to 42 weeks), labor and delivery or imminent labor, and infants under 1 month old. The kidney cutoff matters most in practice because the drug is cleared by the kidneys — the label says impaired excretion carries an increased risk of toxicity, and reduced kidney function also means the drug may not concentrate enough in urine to work. Our own suggestion, not a labeled requirement: kidney function drifts down with age and a normal-looking creatinine can hide it, so an older adult's creatinine clearance is worth calculating before the prescription is filled. One more thing worth knowing: nitrofurantoin only works in the bladder. The label states it is not indicated for pyelonephritis (kidney infection) or perinephric abscess, so flank pain, fever, and vomiting mean a different antibiotic is needed.

Yes, and it is a different risk profile entirely. The chronic lung reaction — diffuse interstitial pneumonitis or pulmonary fibrosis — develops insidiously and, per the FDA label, occurs rarely and generally in patients receiving therapy for six months or longer. That is the group taking nitrofurantoin nightly as prophylaxis for recurrent UTIs, not the person taking it for five days. Chronic active hepatitis and peripheral neuropathy also cluster in long-term use. The label calls for close monitoring of the pulmonary condition of patients on long-term therapy and periodic monitoring of renal function, so any new dry cough or breathlessness that creeps in over weeks should be reported rather than blamed on age or a cold.

Reduced kidney function is the biggest amplifier — it is both a contraindication and, per the label, a condition that may enhance the occurrence of peripheral neuropathy. The label names the same list for neuropathy risk: renal impairment, anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating disease. Two practical items: antacids containing magnesium trisilicate reduce both the rate and extent of nitrofurantoin absorption, so separate them; and G6PD deficiency raises hemolytic anemia risk, which is also why the drug is contraindicated in infants under a month and why the label advises against use while nursing an infant under 1 month old or one known or suspected to be G6PD-deficient.